MedTrace Logo

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

NCT03799718 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-12-04

Study results available
· View outcomes & findings →

Summary

A multidose open-label study with autologous Mesenchymal Stromal Stem Cells Secreting Neurotrophic Factors (MSC-NTF cells) involving 20 participants with progressive MS at multiple investigational study sites.

Conditions

  • Multiple Sclerosis, Chronic Progressive

Interventions

BIOLOGICAL

NurOwn (MSC-NTF cells)

Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors

Sponsors & Collaborators

  • Brainstorm-Cell Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jeffrey Cohen, MD · The Cleveland Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-13
Primary Completion
2021-03-11
Completion
2021-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03799718 on ClinicalTrials.gov